Physician profile
Robert Goldfarb
NPI 1366732547
$8,747.47
in general payments reported to CMS, 2019-2025
45 companies · $1,393 in 2025
The $1,393 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $435 · 2021: $1,149 · 2022: $1,663 · 2023: $1,955 · 2024: $1,564 · 2025: $1,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,812 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,811.79 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,257.13 | 2019-2025 | Ams 700, Ams 800 Artificial Urinary Sphincter, Ams 700 Cxr Rte Kit |
| Abbvie INC. | $685.22 | 2020-2025 | |
| Teleflex LLC | $669.61 | 2021-2025 | Urolift, Barrigel |
| Coloplast Corp | $642.34 | 2019-2025 | Titan, Speedicath |
| Astellas Pharma US INC | $585.35 | 2019-2025 | Myrbetriq, Xtandi, Veozah |
| Antares Pharma, INC. | $572.71 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Janssen Biotech, INC. | $566.65 | 2019-2024 | Erleada, Akeega, Balversa |
| Endo Pharmaceuticals INC. | $461.81 | 2019-2023 | Xiaflex, Edex, Aveed |
| Urovant Sciences INC | $350.56 | 2021-2022 | |
| Urogen Pharma, INC. | $254.76 | 2021-2025 | Jelmyto |
| Bayer Healthcare Pharmaceuticals INC. | $248.43 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $225.14 | 2023-2025 | Gemtesa, Orgovyx |
| Progenics Pharmaceuticals, INC. | $203.45 | 2022-2025 | Pylarify |
| Medtronic, INC. | $171.38 | 2021-2023 | Interstim |
| Merck Sharp & Dohme LLC | $144.27 | 2021-2025 | Keytruda, Keytruda Qlex |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Goldfarb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.